Receptor, Cannabinoid, CB2
"Receptor, Cannabinoid, CB2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of cannabinoid receptor found primarily on immune cells where it may play a role modulating release of CYTOKINES.
| Descriptor ID |
D043885
|
| MeSH Number(s) |
D12.776.543.750.695.125.200
|
| Concept/Terms |
Receptor, Cannabinoid, CB2- Receptor, Cannabinoid, CB2
- CB2 Receptor
- Receptor, CB2
- Cannabinoid Receptor CB2
- CB2, Cannabinoid Receptor
- Receptor CB2, Cannabinoid
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Cannabinoid, CB2".
Below are MeSH descriptors whose meaning is more specific than "Receptor, Cannabinoid, CB2".
This graph shows the total number of publications written about "Receptor, Cannabinoid, CB2" by people in this website by year, and whether "Receptor, Cannabinoid, CB2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, Cannabinoid, CB2" by people in Profiles.
-
Daniels KE, Luginbuhl AJ, Mardekian SK, Cognetti DM, Curry JM, South AP. Assessment of quality and consistency of monoclonal antibodies for CB1 and CB2 in head and neck squamous cell carcinoma. Head Neck. 2019 09; 41(9):3105-3113.
-
Myers AM, Siegele PB, Foss JD, Tuma RF, Ward SJ. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. Br J Pharmacol. 2019 05; 176(10):1552-1567.
-
Ward SJ, Castelli F, Reichenbach ZW, Tuma RF. Surprising outcomes in cannabinoid CB1/CB2 receptor double knockout mice in two models of ischemia. Life Sci. 2018 Feb 15; 195:1-5.
-
Ronca RD, Myers AM, Ganea D, Tuma RF, Walker EA, Ward SJ. A selective cannabinoid CB2 agonist attenuates damage and improves memory retention following stroke in mice. Life Sci. 2015 Oct 01; 138:72-7.
-
Amenta PS, Jallo JI, Tuma RF, Hooper DC, Elliott MB. Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury. J Neuroinflammation. 2014 Nov 22; 11:191.
-
Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014 Nov 01; 144:12-41.
-
Brailoiu GC, Deliu E, Marcu J, Hoffman NE, Console-Bram L, Zhao P, Madesh M, Abood ME, Brailoiu E. Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. Biochemistry. 2014 Aug 05; 53(30):4990-9.
-
Amenta PS, Jallo JI, Tuma RF, Elliott MB. A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J Neurosci Res. 2012 Dec; 90(12):2293-305.
-
Elliott MB, Tuma RF, Amenta PS, Barbe MF, Jallo JI. Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury. J Neurotrauma. 2011 Jun; 28(6):973-81.
-
Chen XP, Yang W, Fan Y, Luo JS, Hong K, Wang Z, Yan JF, Chen X, Lu JX, Benovic JL, Zhou NM. Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i). Br J Pharmacol. 2010 Dec; 161(8):1817-34.